Notícias

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

A seven-holding portfolio promising $12,500 a month sounds straightforward until you examine whose money is actually funding some of those distributions, and why the highest-yielding positions have the weakest claim to keeping their promises.

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.

Investing.com -- Between winding down some legacy operations, executing major cost-cutting initiatives and navigating skyrocketing freight and fuel costs, J&J Snack Foods is going through something of a transition year.

AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.

Jim Cramer called the JNJ dip a buying opportunity live on air, but the data behind his reasoning had already been published hours earlier, and the stock's recent performance tells a very different story than a typical defensive play.

Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.

Ahead of CPI data and the Fed's rate decision, defensive stocks McDonald's, Johnson & Johnson, Walmart, Berkshire Hathaway, and NextEra Energy offer stability and dividends amid market uncertainty.

Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.

JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.

Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...

Etentamig could expand treatment after CAR-T therapy without immediately displacing J&J's fast-growing Carvykti franchise.

Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.

Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.

A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.

Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.

AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.

If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

Management's story has pivoted from concrete wins today to a distant, AI-powered future, a move that coincides with declining revenue in its core business.